vs
LIGAND PHARMACEUTICALS INC（LGND）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
LIGAND PHARMACEUTICALS INC的季度营收约是REGIS CORP的1.0倍（$59.7M vs $57.1M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs 0.8%，领先74.3%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs 22.3%），LIGAND PHARMACEUTICALS INC自由现金流更多（$45.9M vs $891.0K），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs 7.8%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
LGND vs RGS — 直观对比
营收规模更大
LGND
是对方的1.0倍
$57.1M
营收增速更快
LGND
高出17.1%
22.3%
净利率更高
LGND
高出74.3%
0.8%
自由现金流更多
LGND
多$45.0M
$891.0K
两年增速更快
LGND
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $57.1M |
| 净利润 | $44.8M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | 10.8% |
| 净利率 | 75.1% | 0.8% |
| 营收同比 | 39.4% | 22.3% |
| 净利润同比 | 244.1% | -94.0% |
| 每股收益（稀释后） | $2.42 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNDRGS
| Q4 25 | $59.7M | $57.1M | ||
| Q3 25 | $115.5M | $59.0M | ||
| Q2 25 | $47.6M | $60.4M | ||
| Q1 25 | $45.3M | $57.0M | ||
| Q4 24 | $42.8M | $46.7M | ||
| Q3 24 | $51.8M | $46.1M | ||
| Q2 24 | $41.5M | $49.4M | ||
| Q1 24 | $31.0M | $49.2M |
净利润LGNDRGS
| Q4 25 | $44.8M | $456.0K | ||
| Q3 25 | $117.3M | $1.4M | ||
| Q2 25 | $4.8M | $116.5M | ||
| Q1 25 | $-42.5M | $250.0K | ||
| Q4 24 | $-31.1M | $7.6M | ||
| Q3 24 | $-7.2M | $-853.0K | ||
| Q2 24 | $-51.9M | $91.2M | ||
| Q1 24 | $86.1M | $-2.3M |
营业利润率LGNDRGS
| Q4 25 | 23.2% | 10.8% | ||
| Q3 25 | 47.6% | 10.0% | ||
| Q2 25 | 17.7% | 12.1% | ||
| Q1 25 | -79.9% | 8.8% | ||
| Q4 24 | -22.5% | 11.8% | ||
| Q3 24 | 6.1% | 4.6% | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | 9.6% | 8.3% |
净利率LGNDRGS
| Q4 25 | 75.1% | 0.8% | ||
| Q3 25 | 101.6% | 2.3% | ||
| Q2 25 | 10.2% | 192.9% | ||
| Q1 25 | -93.6% | 0.4% | ||
| Q4 24 | -72.6% | 16.4% | ||
| Q3 24 | -13.8% | -1.9% | ||
| Q2 24 | -125.0% | 184.7% | ||
| Q1 24 | 278.1% | -4.7% |
每股收益（稀释后）LGNDRGS
| Q4 25 | $2.42 | $0.16 | ||
| Q3 25 | $5.68 | $0.49 | ||
| Q2 25 | $0.24 | $43.67 | ||
| Q1 25 | $-2.21 | $0.08 | ||
| Q4 24 | $-1.70 | $2.71 | ||
| Q3 24 | $-0.39 | $-0.36 | ||
| Q2 24 | $-2.88 | $38.40 | ||
| Q1 24 | $4.75 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $1.0B | $188.7M |
| 总资产 | $1.6B | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资LGNDRGS
| Q4 25 | $733.5M | $18.4M | ||
| Q3 25 | $664.5M | $16.6M | ||
| Q2 25 | $245.0M | $17.0M | ||
| Q1 25 | $208.9M | $13.3M | ||
| Q4 24 | $256.2M | $10.2M | ||
| Q3 24 | $219.6M | $6.3M | ||
| Q2 24 | $226.9M | $10.1M | ||
| Q1 24 | $310.6M | $5.9M |
总债务LGNDRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益LGNDRGS
| Q4 25 | $1.0B | $188.7M | ||
| Q3 25 | $950.2M | $187.6M | ||
| Q2 25 | $828.5M | $185.6M | ||
| Q1 25 | $795.5M | $68.6M | ||
| Q4 24 | $830.4M | $66.7M | ||
| Q3 24 | $841.2M | $56.4M | ||
| Q2 24 | $775.2M | $56.8M | ||
| Q1 24 | $806.5M | $-35.8M |
总资产LGNDRGS
| Q4 25 | $1.6B | $588.3M | ||
| Q3 25 | $1.5B | $592.1M | ||
| Q2 25 | $948.6M | $599.0M | ||
| Q1 25 | $905.4M | $511.2M | ||
| Q4 24 | $941.8M | $530.1M | ||
| Q3 24 | $954.9M | $508.9M | ||
| Q2 24 | $866.4M | $530.5M | ||
| Q1 24 | $913.9M | $543.7M |
负债/权益比LGNDRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $891.0K |
| 自由现金流率自由现金流/营收 | 76.9% | 1.6% |
| 资本支出强度资本支出/营收 | 0.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.03× | 3.65× |
| 过去12个月自由现金流最近4个季度 | $48.9M | $14.9M |
8季度趋势，按日历期对齐
经营现金流LGNDRGS
| Q4 25 | $45.9M | $1.7M | ||
| Q3 25 | $13.1M | $2.3M | ||
| Q2 25 | $15.8M | $6.8M | ||
| Q1 25 | $-25.4M | $6.2M | ||
| Q4 24 | $28.5M | $2.1M | ||
| Q3 24 | $36.5M | $-1.3M | ||
| Q2 24 | $13.3M | $5.1M | ||
| Q1 24 | $18.7M | $-277.0K |
自由现金流LGNDRGS
| Q4 25 | $45.9M | $891.0K | ||
| Q3 25 | $13.1M | $1.9M | ||
| Q2 25 | $15.6M | $6.2M | ||
| Q1 25 | $-25.7M | $5.9M | ||
| Q4 24 | $27.8M | $1.7M | ||
| Q3 24 | $35.9M | $-1.4M | ||
| Q2 24 | $12.9M | $5.1M | ||
| Q1 24 | $18.6M | $-326.0K |
自由现金流率LGNDRGS
| Q4 25 | 76.9% | 1.6% | ||
| Q3 25 | 11.3% | 3.2% | ||
| Q2 25 | 32.7% | 10.3% | ||
| Q1 25 | -56.6% | 10.3% | ||
| Q4 24 | 64.8% | 3.6% | ||
| Q3 24 | 69.4% | -3.0% | ||
| Q2 24 | 31.1% | 10.3% | ||
| Q1 24 | 60.1% | -0.7% |
资本支出强度LGNDRGS
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.4% | 0.9% | ||
| Q1 25 | 0.5% | 0.6% | ||
| Q4 24 | 1.7% | 0.9% | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.0% | 0.0% | ||
| Q1 24 | 0.3% | 0.1% |
现金转化率LGNDRGS
| Q4 25 | 1.03× | 3.65× | ||
| Q3 25 | 0.11× | 1.68× | ||
| Q2 25 | 3.26× | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
